Literature DB >> 23474780

Skin side effects of inflammatory bowel disease therapy.

Joana Torres1, Sébastien Buche, Emmanuel Delaporte, Jean-Frédéric Colombel.   

Abstract

Skin manifestations are common in patients suffering from inflammatory bowel disease (IBD) and can be associated with the disease itself, with nutritional deficiencies, or with therapy. All drugs currently used for treating IBD have the potential to cause dermatologic manifestations that can have a wide range of clinical presentations, from mild drug eruptions to potentially life-threatening immune-mediated reactions. The wider use of thiopurines and anti-tumor necrosis factor in the past years has led to the recognition of 2 more skin complications of IBD therapy: the potentially disfiguring non-melanoma skin cancer associated with the current or past use of thiopurines and the paradoxical new onset or exacerbation of anti-tumor necrosis factor-associated psoriasis. Despite being rare, these complications can be severe and lead to therapy discontinuation, and therefore, gastroenterologists need to become familiar with their epidemiology, diagnosis, and management. Herein, we reviewed the skin side effects of IBD therapy, specially focusing in thiopurines and anti-tumor necrosis factor therapy and in the recently described skin cancer and psoriasis, and we tried to advance some practical algorithms that can provide some help to the clinicians dealing with these complications in their day-by-day practice.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23474780     DOI: 10.1097/MIB.0b013e3182802c07

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  10 in total

Review 1.  ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease.

Authors:  Francis A Farraye; Gil Y Melmed; Gary R Lichtenstein; Sunanda V Kane
Journal:  Am J Gastroenterol       Date:  2017-01-10       Impact factor: 10.864

Review 2.  Crohn's disease and skin.

Authors:  A G Gravina; A Federico; E Ruocco; A Lo Schiavo; F Romano; A Miranda; D Sgambato; M Dallio; V Ruocco; C Loguercio; M Romano
Journal:  United European Gastroenterol J       Date:  2015-08-21       Impact factor: 4.623

3.  Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience.

Authors:  Estelle Fréling; Cédric Baumann; Jean-François Cuny; Marc-André Bigard; Jean-Luc Schmutz; Annick Barbaud; Laurent Peyrin-Biroulet
Journal:  Am J Gastroenterol       Date:  2015-07-21       Impact factor: 10.864

4.  Real-life burden of adverse reactions to biological therapy in inflammatory bowel disease: a single-centre prospective case series.

Authors:  Tiziana Larussa; Antonio Basile; Caterina Palleria; Chiara Iannelli; Ada Vero; Lidia Giubilei; Caterina De Sarro; Evelina Suraci; Raffaella Marasco; Maria Imeneo; Emilio Russo; Ludovico Abenavoli; Giovambattista De Sarro; Francesco Luzza
Journal:  Med Pharm Rep       Date:  2021-07-29

5.  Successful Treatment of Ulcerative Colitis With Vedolizumab in a Patient With an Infliximab-Associated Psoriasiform Rash.

Authors:  Ayal Hirsch; Ruben J Colman; Gabriel D Lang; David T Rubin
Journal:  ACG Case Rep J       Date:  2015-07-09

6.  Preventative care for patients with inflammatory bowel disease in the Veterans Health Administration.

Authors:  Nivedita Pandey; Henry H Herrera; Christopher M Johnson; Andrea A MacCarthy; Laurel A Copeland
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

Review 7.  Roles of Dietary Amino Acids and Their Metabolites in Pathogenesis of Inflammatory Bowel Disease.

Authors:  Xianying Bao; Zemeng Feng; Jiming Yao; Tiejun Li; Yulong Yin
Journal:  Mediators Inflamm       Date:  2017-03-14       Impact factor: 4.711

8.  Clinical approach to skin eruptions induced by anti-TNF agents among patients with inflammatory bowel diseases: insights from a multidisciplinary IBD-DERMA clinic.

Authors:  Henit Yanai; Hadar Amir Barak; Jacob E Ollech; Irit Avni Biron; Idan Goren; Yifat Snir; Hagar Banai Eran; Yelena Broitman; Maya Aharoni Golan; Elena Didkovsky; Iris Amitay-Laish; Ayelet Ollech; Emmilia Hodak; Iris Dotan; Lev Pavlovsky
Journal:  Therap Adv Gastroenterol       Date:  2021-11-08       Impact factor: 4.409

9.  Anti-Tumor Necrosis Factor-α-Induced Dermatological Complications in a Large Cohort of Inflammatory Bowel Disease Patients.

Authors:  P Andrade; S Lopes; R Gaspar; A Nunes; S Magina; G Macedo
Journal:  Dig Dis Sci       Date:  2018-01-18       Impact factor: 3.487

10.  Dermatological Manifestations in Pediatric Inflammatory Bowel Disease.

Authors:  Smaranda Diaconescu; Silvia Strat; Gheorghe G Balan; Carmen Anton; Gabriela Stefanescu; Ileana Ioniuc; Ana Maria Alexandra Stanescu
Journal:  Medicina (Kaunas)       Date:  2020-08-23       Impact factor: 2.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.